Share on StockTwits
 

Covance (NYSE:CVD) Insider Brian H. Nutt sold 1,808 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $100.12, for a total transaction of $181,016.96. Following the sale, the insider now directly owns 1,099 shares of the company’s stock, valued at approximately $110,032. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Covance (NYSE:CVD) traded down 0.16% on Tuesday, hitting $100.07. 477,537 shares of the company’s stock traded hands. Covance has a 52-week low of $65.40 and a 52-week high of $100.76. The stock’s 50-day moving average is $92.75 and its 200-day moving average is $86.95. The company has a market cap of $5.506 billion and a P/E ratio of 31.82.

Covance (NYSE:CVD) last announced its earnings results on Tuesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.03. The company had revenue of $623.00 million for the quarter, compared to the consensus estimate of $613.80 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts predict that Covance will post $3.87 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank raised their price target on shares of Covance from $81.00 to $97.00 in a research note on Thursday, February 6th. They now have a “hold” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Covance from $105.00 to $115.00 in a research note on Thursday, February 6th. Finally, analysts at Goldman Sachs downgraded shares of Covance from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 21st. They now have a $101.00 price target on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. Covance currently has a consensus rating of “Hold” and an average target price of $89.09.

Covance Inc is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.